Cargando…
Targeting of CD122 enhances antitumor immunity by altering the tumor immune environment
Mounting evidence demonstrates that CD8(+)CD122(+) T cells have suppressive properties with the capacity to inhibit T cell responses. Therefore, these cells are rational targets for cancer immunotherapy. Here, we demonstrate that CD122 monoclonal antibody (mAb; aCD122) therapy significantly suppress...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752510/ https://www.ncbi.nlm.nih.gov/pubmed/29312597 http://dx.doi.org/10.18632/oncotarget.22642 |